Abstract | CONTEXT: Imaging with [¹²³I] iodometomidate ([¹²³I]IMTO) has been shown to diagnose adrenocortical lesions with high sensitivity and specificity. OBJECTIVE: DESIGN: We conducted a prospective monocentric diagnostic study and a prospective case series at a single tertiary referral center. PATIENTS AND INTERVENTIONS: Fifty-eight patients with histologically confirmed ACC, all European Network for the Study of Adrenal Tumors stage IV (with distant metastases), received 185 MBq [¹²³I]IMTO. Sequential planar whole-body scans until 24 hours post injection and single photon emission computed tomography/computed tomography (SPECT/CT) hybrid imaging 4 to 6 hours post injection were performed. MAIN OUTCOME MEASURES: Outcome measures included uptake of [¹²³I]IMTO in ACC lesions, sensitivity and specificity of [¹²³I]IMTO imaging compared with conventional imaging, and number of patients eligible for [¹³¹I]IMTO therapy. RESULTS: Of 430 lesions detected by conventional imaging, 30% showed strong, 8% moderate, and 62% no tracer accumulation. [¹²³I]IMTO detected both primary and metastatic lesions of ACC. However, a substantial percentage of lesions failed to show [¹²³I]IMTO uptake. The overall sensitivity and specificity values were 38% and 100%, respectively. Thirty-four patients (59%) had at least 1 [¹²³I]IMTO-positive lesion. Cortisol and aldosterone secretion by ACC was positively correlated to [¹²³I]IMTO uptake (P = .01); cytotoxic chemotherapy and mitotane treatment presumably did not influence tracer uptake. Twenty-one patients (36.2%) had radiotracer uptake in all lesions ≥ 2 cm and therefore were potential candidates for targeted systemic radiotherapy with [¹³¹I]IMTO. CONCLUSION: About one-third of patients with ACC show specific retention of [¹²³I]IMTO in metastatic lesions. This study provides support for the conduct of a prospective trial to determine whether the first molecular informed therapy using [¹³¹I]IMTO will be of value to patients with metastatic ACC.
|
Authors | Michael C Kreissl, Andreas Schirbel, Martin Fassnacht, Heribert Haenscheid, Frederik A Verburg, Stefanie Bock, Wolfgang Saeger, Pascal Knoedler, Christoph Reiners, Andreas K Buck, Bruno Allolio, Stefanie Hahner |
Journal | The Journal of clinical endocrinology and metabolism
(J Clin Endocrinol Metab)
Vol. 98
Issue 7
Pg. 2755-64
(Jul 2013)
ISSN: 1945-7197 [Electronic] United States |
PMID | 23609836
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Iodine Radioisotopes
- Radiopharmaceuticals
- iodophenyl metomidate
- Aldosterone
- Hydrocortisone
- Etomidate
|
Topics |
- Adrenal Cortex
(diagnostic imaging, metabolism, pathology)
- Adrenal Cortex Neoplasms
(blood, diagnostic imaging, metabolism, pathology)
- Adrenocortical Carcinoma
(diagnostic imaging, metabolism, pathology, secondary)
- Adult
- Aged
- Aldosterone
(blood, metabolism)
- Cohort Studies
- Etomidate
(analogs & derivatives, pharmacokinetics)
- Female
- Humans
- Hydrocortisone
(blood, metabolism)
- Iodine Radioisotopes
(pharmacokinetics)
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(diagnostic imaging, metabolism, pathology)
- Neoplasm Staging
- Pilot Projects
- Prospective Studies
- Radiopharmaceuticals
(pharmacokinetics)
- Sensitivity and Specificity
- Tomography, Emission-Computed, Single-Photon
- Tomography, X-Ray Computed
- Whole Body Imaging
|